Stefan Sleijfer
#142,135
Most Influential Person Now
Researcher
Stefan Sleijfer's AcademicInfluence.com Rankings
Stefan Sleijfermedical Degrees
Medical
#2587
World Rank
#3017
Historical Rank
Oncology
#163
World Rank
#169
Historical Rank
Stefan Sleijferlaw Degrees
Law
#2555
World Rank
#3181
Historical Rank
Common Law
#112
World Rank
#121
Historical Rank
Download Badge
Medical Law
Stefan Sleijfer's Degrees
- PhD Biomedical Sciences Erasmus University Rotterdam
- Masters Biomedical Sciences University of Amsterdam
- Bachelors Biomedical Sciences University of Amsterdam
Why Is Stefan Sleijfer Influential?
(Suggest an Edit or Addition)Stefan Sleijfer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. (2006) (809)
- Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (624)
- Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). (2009) (611)
- Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. (2013) (559)
- Bleomycin-induced pneumonitis. (2001) (547)
- Pan-cancer whole-genome analyses of metastatic solid tumours (2018) (526)
- Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells (2009) (450)
- Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. (2011) (317)
- Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. (2009) (275)
- Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (254)
- Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (244)
- Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels (2010) (239)
- Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. (2015) (231)
- Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (230)
- Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (216)
- mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients (2011) (209)
- Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2021) (206)
- Side Effects of Interferon-α Therapy (2005) (202)
- Circulating tumor cell isolation and diagnostics: toward routine clinical use. (2011) (200)
- Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience (2013) (199)
- Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcom (2010) (194)
- Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR (2009) (184)
- The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies (2019) (179)
- Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response (2008) (174)
- Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis (2018) (173)
- Designing transformative clinical trials in the cancer genome era. (2013) (150)
- Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. (2014) (149)
- Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (147)
- MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer (2011) (133)
- The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. (2016) (132)
- Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (131)
- KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue (2013) (130)
- (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. (2010) (130)
- The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs (2019) (125)
- Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis (2017) (120)
- The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-Like Syndrome With Activation of the Endothelin System (2011) (120)
- Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions (2017) (114)
- Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. (2012) (114)
- Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (112)
- Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Tr (2017) (110)
- The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact (2019) (110)
- Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. (2009) (110)
- PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma (2017) (109)
- Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146 (2011) (107)
- Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress (2012) (106)
- Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study (2009) (105)
- External quality assurance of circulating tumor cell enumeration using the CellSearch® system: A feasibility study (2011) (105)
- Circulating tumour cell detection on its way to routine diagnostic implementation? (2007) (105)
- TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer (2018) (103)
- The potential of statins as part of anti-cancer treatment. (2005) (101)
- Circulating endothelial cells in oncology: pitfalls and promises (2008) (101)
- Breast cancer genomics and immuno-oncological markers to guide immune therapies. (2017) (99)
- Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. (2017) (98)
- Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview. (2016) (98)
- Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo (2007) (98)
- Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. (2011) (94)
- Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. (2014) (89)
- Molecular Tumor Boards: current practice and future needs (2017) (89)
- The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator? (2008) (86)
- Corrections to "Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2018) (86)
- Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes (2011) (85)
- Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. (2005) (85)
- Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2021) (85)
- Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (84)
- Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients (2011) (83)
- Bone sarcomas: ESMO-EURACAN-GENTURIS-ERNPaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. (2021) (83)
- MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours (2013) (81)
- Side effects of interferon-alpha therapy. (2005) (81)
- The applicability of mTOR inhibition in solid tumors. (2009) (80)
- Cells meeting our immunophenotypic criteria of endothelial cells are large platelets (2007) (79)
- Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment (2008) (79)
- Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours (2014) (78)
- Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects (2009) (75)
- Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material (2016) (74)
- The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. (2007) (73)
- Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib: Preclinical Study (2014) (72)
- Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors (2015) (72)
- Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (71)
- Circulating tumor cells and sample size: the more, the better. (2010) (70)
- 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up (2018) (68)
- ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients. (2017) (68)
- Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. (2007) (66)
- Dose selection in phase I studies: why we should always go for the top. (2008) (65)
- TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu (2013) (65)
- Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. (2013) (65)
- BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib (2012) (64)
- Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. (2013) (61)
- MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR‐145 and miR‐451 as tumor suppressors (2014) (61)
- Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells (2014) (60)
- High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer (2011) (60)
- The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? (2008) (59)
- Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. (2010) (59)
- Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors (2012) (58)
- Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts. (2018) (58)
- Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? (2015) (58)
- Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. (2010) (57)
- Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials (2019) (57)
- The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. (2010) (54)
- A new approach for rapid and reliable enumeration of circulating endothelial cells in patients (2012) (54)
- CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. (2012) (54)
- Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. (1995) (53)
- Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer (2010) (53)
- A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities (2015) (53)
- Tumor cell expression of immune inhibitory molecules and tumor‐infiltrating lymphocyte count predict cancer‐specific survival in pancreatic and ampullary cancer (2017) (52)
- The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. (2011) (52)
- Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy (2014) (52)
- Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer. (2019) (51)
- First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors (2015) (51)
- Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature. (2015) (49)
- International study on inter-reader variability for circulating tumor cells in breast cancer (2014) (49)
- Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients (2017) (49)
- Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients (2018) (49)
- High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. (2014) (49)
- Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. (2006) (48)
- Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. (2015) (48)
- CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer (2009) (48)
- Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen (2013) (48)
- Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes (2012) (47)
- Corrections to "Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2018) (47)
- Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience (2014) (46)
- Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. (2016) (45)
- Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. (2015) (45)
- Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. (2014) (45)
- Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. (2010) (44)
- mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients (2015) (44)
- Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (43)
- Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study (2012) (42)
- Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor1 (2016) (42)
- Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer (2009) (41)
- Thalidomide in solid tumours: the resurrection of an old drug. (2004) (41)
- Pazopanib, a new therapy for metastatic soft tissue sarcoma (2013) (41)
- Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin (2009) (41)
- Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients (2012) (41)
- Prognostic value of intra‐tumoral CD8+/FoxP3+ lymphocyte ratio in patients with resected colorectal cancer liver metastasis (2018) (40)
- Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. (2009) (40)
- Radiomics approach to distinguish between well differentiated liposarcomas and lipomas on MRI (2019) (40)
- Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage (2008) (39)
- Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. (2015) (38)
- International expert opinion on patient-tailored management of soft tissue sarcomas. (2014) (38)
- Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer (2016) (38)
- Clinical value of circulating endothelial cell detection in oncology. (2012) (37)
- Induction of tumor necrosis factor‐α as a cause of bleomycin‐related toxicity (1998) (37)
- Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? (2012) (37)
- T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies (2010) (37)
- Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. (2015) (37)
- Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene. (2006) (37)
- Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma (2017) (37)
- Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. (2014) (36)
- Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. (1995) (35)
- Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients (2018) (35)
- The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets (2021) (34)
- Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases (2016) (34)
- Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis (2016) (34)
- Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry. (2016) (34)
- CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab (2019) (34)
- Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area (2015) (34)
- Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043 (2007) (33)
- Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases. (2016) (33)
- Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib (2015) (32)
- Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels (2019) (32)
- It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor–vascular endothelial growth factor receptor pathway in patients with solid malignancies (2010) (32)
- Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. (2018) (32)
- Allele-specific, non-extendable primer blocker PCR (AS-NEPB-PCR) for DNA mutation detection in cancer. (2013) (32)
- Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen (2016) (32)
- High‐throughput isolation of circulating tumor DNA: a comparison of automated platforms (2018) (31)
- Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. (2010) (31)
- Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) (2018) (30)
- Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma (2018) (30)
- Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer (2018) (30)
- Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. (1996) (30)
- Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases (2015) (29)
- The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study. (2012) (28)
- Circulating endothelial cells: a potential parameter of organ damage in sickle cell anemia? (2008) (28)
- RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer (2019) (28)
- Lysosomal Sequestration Determines Intracellular Imatinib Levels (2015) (28)
- Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity (2017) (27)
- Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies. (2017) (27)
- MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α (2014) (26)
- Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA12 (2018) (26)
- European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy. (2018) (26)
- The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases. (2012) (25)
- Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial (2017) (25)
- An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients (2016) (25)
- Denosumab in breast cancer treatment. (2013) (25)
- Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer (2020) (25)
- Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon‐α: Course and relationship with psychiatric status (2008) (25)
- The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer. (2016) (25)
- Angiogenesis inhibition in non-GIST soft tissue sarcomas. (2008) (25)
- Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features (2021) (24)
- Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. (2017) (24)
- Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells. (2021) (23)
- Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis (2008) (23)
- Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy (2020) (23)
- The Price of Success: Cost‐Effectiveness of Molecularly Targeted Agents (2009) (23)
- Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered (2016) (23)
- Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. (2012) (23)
- Differences in recurrence and survival of extremity liposarcoma subtypes. (2018) (23)
- Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review (2019) (23)
- Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules (2014) (23)
- Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature (2008) (22)
- Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer. (2017) (22)
- Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review. (2020) (22)
- Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design (2012) (21)
- Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer (2019) (21)
- T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness. (2014) (21)
- On the origin of (CD105+) circulating endothelial cells (2009) (20)
- AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel (2019) (20)
- T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients (2016) (20)
- Application of prolonged microdialysis sampling in carboplatin-treated cancer patients (2008) (20)
- Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield. (2008) (20)
- Full-blown graft-versus-host disease presenting with skin manifestations, jaundice and diarrhoea: an unusual paraneoplastic phenomenon of a thymoma. (2003) (19)
- Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial (2015) (19)
- Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study (2010) (19)
- Circulating tumor cells and survival in abiraterone‐ and enzalutamide‐treated patients with castration‐resistant prostate cancer (2018) (19)
- Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study (2013) (19)
- The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only (2019) (19)
- Gynaecological sarcomas (2007) (19)
- Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies (2010) (19)
- Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA (2020) (19)
- The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. (2014) (18)
- Influence of pegylated interferon-α therapy on plasma levels of citrulline and arginine in melanoma patients (2006) (17)
- MAGE-C2–Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses (2016) (17)
- Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. (2019) (17)
- Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material (2019) (17)
- First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy. (2017) (16)
- Retroviral vectors for clinical immunogene therapy are stable for up to 9 years (2008) (16)
- Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients (2017) (16)
- Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes (2020) (16)
- Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects (2007) (16)
- Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis. (2019) (16)
- Practical aspects of managing gastrointestinal stromal tumors. (2006) (16)
- A phase 1 study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies. (2005) (16)
- Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. (2014) (16)
- Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated. (2008) (16)
- An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells. (2018) (15)
- Active surveillance in desmoid-type fibromatosis: A systematic literature review. (2020) (15)
- The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies. (2016) (15)
- Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial (2021) (15)
- Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study (2018) (15)
- Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. (2019) (15)
- Adoptive T-cell therapy: a need for standard immune monitoring. (2015) (15)
- Severe sarcopenia might be associated with a decline of physical independence in older patients undergoing chemotherapeutic treatment (2018) (15)
- The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome (2018) (15)
- Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples (2020) (15)
- Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel (2019) (15)
- Combined cytotoxic effects of tumor necrosis factor-alpha with various cytotoxic agents in tumor cell lines that are drug resistant due to mutated p53. (1999) (15)
- Enhanced sensitivity to tumor necrosis factor‐α in doxorubicin‐resistant tumor cell lines due to down‐regulated c‐erbB2 (1998) (14)
- Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out. (2018) (14)
- A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin (2008) (14)
- Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. (2017) (14)
- Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. (2011) (13)
- High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane (2019) (13)
- Circulating endothelial cell enumeration demonstrates prolonged endothelial damage in recipients of myeloablative allogeneic stem cell transplantation (2015) (13)
- Management of aggressive fibromatosis: can we unravel the maze of treatment options? (2009) (13)
- Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes. (2004) (13)
- Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia. (2010) (13)
- Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase 1 study in patients with advanced solid malignancies (2006) (12)
- Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs (2019) (12)
- Self-Seeding Microwells to Isolate and Assess the Viability of Single Circulating Tumor Cells (2019) (12)
- Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer (2020) (12)
- Bleomycin and scuba diving: where is the harm? (2007) (12)
- Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy (2017) (12)
- Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors (2017) (12)
- Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials (2019) (12)
- Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer (2020) (11)
- A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein. (2013) (11)
- Impact of primary tumor location on outcome of liposarcoma patients, a retrospective cohort study. (2019) (11)
- Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy (2017) (11)
- Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment. (2016) (11)
- Corrigendum to “Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies” [Cancer Treat. Rev. 40 (2014) 513–522] (2014) (11)
- Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients (2020) (11)
- Sensitive detection of mitochondrial DNA variants for analysis of mitochondrial DNA-enriched extracts from frozen tumor tissue (2018) (11)
- Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics. (2020) (11)
- Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments (2017) (10)
- The role of mitochondrial DNA in breast tumors. (2019) (10)
- Integrating collection of biospecimens in clinical trials: the approach of the European organization for research and treatment of cancer. (2011) (10)
- Aplastic anaemia: a review. (2003) (10)
- Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure (2016) (10)
- EORTC Study 26041–22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma—Results of a phase I trial (2007) (10)
- Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects. (2007) (10)
- Development and validation of an UPLC-MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair. (2015) (10)
- Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry (2016) (10)
- mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells (2010) (9)
- Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities. (2019) (9)
- Effects of hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan on pulmonary function assessments. (1997) (9)
- Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA (2017) (9)
- Differential Diagnosis and Molecular Stratification of Gastrointestinal Stromal Tumors on CT Images Using a Radiomics Approach (2020) (9)
- Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area. (2015) (9)
- An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA. (2019) (9)
- Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery. (2019) (9)
- Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells. (2016) (8)
- Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database (2018) (8)
- Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma. (2008) (8)
- TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2 (2016) (8)
- Novel methods to diagnose leptomeningeal metastases in breast cancer (2018) (8)
- The future of drug development? Seeking evidence of activity of novel drugs in small groups of patients. (2013) (8)
- Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib (2017) (8)
- Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors (2020) (7)
- Medical oncology: Clinical value of circulating tumor cells in breast cancer (2011) (7)
- Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases (2021) (7)
- Cancer clinical trials--do we need a new algorithm in the age of stratified medicine? (2013) (7)
- Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis. (1996) (7)
- A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial (2016) (7)
- Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study (2017) (7)
- EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives. (2018) (7)
- Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors (2020) (7)
- External Quality Assurance of Circulating Tumor Cell Enumeration Using (2011) (7)
- Phase II studies in soft tissue sarcoma: time for reappraisal. (2012) (6)
- Are immune signatures a worthwhile tool for decision making in early-stage human epidermal growth factor receptor 2-positive breast cancer? (2015) (6)
- Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells. (2013) (6)
- mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy (2016) (6)
- Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients (2005) (6)
- Current clinical trials for advanced osteosarcoma and soft tissue sarcoma (2014) (6)
- Successful treatment on an out-patient basis of a patient with Down's syndrome and disseminated testicular seminoma. (1996) (6)
- Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers (2018) (6)
- Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report (2017) (6)
- Reproducible radiomics through automated machine learning validated on twelve clinical applications (2021) (6)
- First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours. (2022) (6)
- Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors. (2012) (6)
- B-cell clusters at the invasive margin associate with longer survival in early-stage oral-tongue cancer patients (2021) (5)
- Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies (2008) (5)
- Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study (2017) (5)
- Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. (2019) (5)
- Assessing the Desmoid-Type Fibromatosis Patients' Voice: Comparison of Health-Related Quality of Life Experiences from Patients of Two Countries (2020) (5)
- Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation (2021) (5)
- Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS). (2014) (5)
- Pan-cancer whole-genome analyses of metastatic solid tumours (2019) (5)
- Health policy: Affordability of drugs used in oncology health care (2016) (5)
- Biliary Excretion of Imatinib and Its Active Metabolite CGP74588 During Severe Hepatic Dysfunction (2012) (5)
- The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)—A Protocol for an International Cohort Study (2021) (5)
- The WORC* database: MRI and CT scans, segmentations, and clinical labels for 930 patients from six radiomics studies (2021) (5)
- High-dose methotrexate, vincristine and cisplatin as salvage treatment for relapsed non-seminomatous germ-cell cancer. (1995) (5)
- Quantification of Circulating Endothelial Cells by Flow Cytometry (2009) (5)
- Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors (2019) (5)
- 444OPHASE IB TRIAL TRIAL OF RG7116, A GLYCOENGINEERED MONOCLONAL ANTIBODY TARGETING HER3, IN COMBINATION WITH CETUXIMAB OR ERLOTINIB IN PATIENTS WITH ADVANCED/METASTATIC TUMORS OF EPITHELIAL CELL ORIGIN EXPRESSING HER3 PROTEIN. (2014) (4)
- A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity (2021) (4)
- The BRAF P.V600E Mutation Status of Melanoma Lung Metastases Cannot Be Discriminated on Computed Tomography by LIDC Criteria nor Radiomics Using Machine Learning (2021) (4)
- Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis (2022) (4)
- CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer (2020) (4)
- Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Population-Based Study. (2019) (4)
- Evidence on the cost of breast cancer drugs is required for rational decision making (2018) (4)
- The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC. (2022) (4)
- “It's the Economy, Stupid”: Strategies for Improved Cost Containment in Cancer Treatment (2014) (4)
- In desmoid-type fibromatosis cells sorafenib induces ferroptosis and apoptosis, which are enhanced by autophagy inhibition. (2022) (4)
- With a little help from small friends: Enhanced chemotherapeutic effects with imatinib. (2006) (3)
- A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOG) side study. (2013) (3)
- Circulating tumor cell-driven use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. (2021) (3)
- Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-α therapy (2008) (3)
- Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review. (2022) (3)
- Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts): An EORTC-STBSG study. (2010) (3)
- Tyrosine kinase inhibitors and QTc intervals: A class effect. (2014) (3)
- Tumour necrosis factor: the decline and fall of a biological agent and its resurrection. (1994) (3)
- Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations. (2019) (3)
- The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer (2021) (3)
- Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (2022) (3)
- A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients (2021) (3)
- Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features (2021) (3)
- How to decide whether to offer and use "nonstandard" therapies in patients with advanced sarcomas and gastrointestinal stromal tumors: global variations in clinical practice, assessment, and access to therapies in diseases with limited incidence and data. (2012) (3)
- Intratumoral Niches of B Cells and Follicular Helper T Cells, and the Absence of Regulatory T Cells, Associate with Longer Survival in Early-Stage Oral Tongue Cancer Patients (2022) (3)
- Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like–Induced Protein Changes in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Throughout Disease Progression (2022) (3)
- Phase I safety and pharmacokinetic (PK) study of sunitinib (S) in combination with ifosfamide (I) in patients (pts) with advanced solid tumors (STs). (2016) (2)
- Tumor volumes measurement (3D) versus Response Evaluation Criteria in Solid Tumors (RECIST version 1.1, 1D) and Choi criteria (C) in assessing response of gastrointestinal stromal tumors (GIST) to imatinib (IM). (2011) (2)
- Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: Translational results of EORTC trial 62052. (2013) (2)
- Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer (2009) (2)
- Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. (2022) (2)
- Abstract GS1-07: The genomic landscape of 501 metastatic breast cancer patients (2019) (2)
- CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients. (2022) (2)
- Single-dimension CT measurements with RECIST 1.1 to evaluate liver metastases in GIST patients on imatinib (Abstract) (2012) (2)
- Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer? (2005) (2)
- MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma (2019) (2)
- Editorial: the long and winding road to better cancer cell-specific therapies. (2008) (2)
- High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments (2021) (2)
- The inhibition of CCR2 to modify the microenvironment in pancreatic cancer mouse model and to support the profiling of the CCR2 inhibitor CCX872-B in patients. (2016) (2)
- 1496PEORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: Clinical profile and response to systemic therapy (2017) (2)
- Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients (2013) (2)
- 1502PEvolution in neutrophil-to-lymphocyte ratio (NLR) among advanced soft tissue sarcoma (STS) patients treated with pazopanib within EORTC 62043/62072 trials (2017) (2)
- GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design. (2008) (2)
- Abstract P6-04-08: FOXA1 expression: regulated by EZH2 and associated with favorable outcome to tamoxifen in advanced breast cancer (2012) (2)
- Potential Biomarkers in Metastatic Gastrointestinal Stromal Tumors (2007) (2)
- Physical activity in long-term survivors of germ-cell cancer. (2003) (2)
- Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs). (2012) (2)
- Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor Outcomes (2022) (2)
- Decreased expression of EZH 2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer (2019) (2)
- Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors (2020) (2)
- Age as a prognostic factor for outcome in patients (pts) with rhabdomyosarcoma (RMS) (2008) (2)
- Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing (2022) (2)
- Correlation between nivolumab exposure and treatment outcome in NSCLC. (2018) (2)
- Soft tissue and visceral sarcomas (1)
- Adoptive therapy with TCR gene-engineered T cells to treat patients with MAGE-C2-positive melanoma and head and neck cancer (2020) (1)
- Imatinib‐induced agranulocytosis in patients with gastrointestinal stromal tumors (2015) (1)
- Abstract P4-07-01: Correlation of Breast Cancer Susceptibility Loci with Patient Characteristics, Metastasis-Free Survival and Expression of the Nearest Genes (2010) (1)
- Abstract 1450: MicroRNAs in myxoid/round cell liposarcomas: FUS-CHOP regulated miR-497 and miR-30a target the insulin-like growth factor receptor pathway (2014) (1)
- A Nationwide Prospective Clinical Trial on Active Surveillance in Patients With Non-intraabdominal Desmoid-type Fibromatosis (2022) (1)
- Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study. (2017) (1)
- Letter to the editor: Comments on 'A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation'. (2020) (1)
- CYP-2C19*2Predicts Favorable Outcome of Tamoxifen Treatment for Advanced Breast Cancer. (2009) (1)
- Adoptive Engineered T-Cell Trials to Achieve Cancer Killing (ATTACK). (2015) (1)
- Phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): First-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent administered on days 1, 4, 8, and 11 of a 21-day cycle. (2010) (1)
- Lysosomal Sequestration Determines Intracellular Imatinib Levels s (2015) (1)
- 2OExpanding the use of approved drugs: The CPCT’s Drug Rediscovery Protocol (DRUP) (2017) (1)
- The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies (2019) (1)
- Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenon. (2008) (1)
- High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments (2021) (1)
- Abstract B24: Pharmacokinetic and pharmacodynamic profile of the novel, oral and selective CCR2 inhibitor CCX872-B in a Phase 1B pancreatic cancer trial (2015) (1)
- Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis (2016) (1)
- 1OAssociation between single nucleotide polymorphisms and side effects in nivolumab treated NSCLC patients (2016) (1)
- APOBEC driving genomic evolution in ER+/HER2- breast cancer (2020) (1)
- Abstract 3409: Generation of mRNA and miRNA gene expression profiles in circulating tumor cells of metastatic colorectal cancer patients (2012) (1)
- Pazopanib for patients with advanced soft tissue sarcomas in a real‐life setting (2016) (1)
- Adjuvant treatment in patients with melanoma: The planning of scanning. (2021) (1)
- Gastrointestinal Stromal Tumors (2006) (1)
- 579 Phase I and Pharmacokinetic (PK) Study of Pazopanib in Combination with Two Schedules of Docetaxel (D) in Patients (pts) with Advanced Solid Tumors (2012) (1)
- Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data (2021) (1)
- CD276-positive circulating endothelial cells in advanced colorectal cancer. (2019) (1)
- [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]. (2008) (1)
- Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients (2019) (1)
- International study on inter-reader variability for circulating tumor cells in breast cancer (2014) (1)
- The Prognostic Role of b -Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only A Meta-analysis of individual Patient Data M ETA -A NALYSIS (1)
- 441 Quality Assurance of Biomarker Assays in Clinical Trials (2012) (1)
- Pulmonary Alterations During BEP? Always Be Aware Of BIP (2007) (1)
- Circulating tumor cells do not correspond with clinicopathological characteristics of muscle-invasive bladder cancer patients undergoing radical cystectomy: Interim results of the CirGuidance study (2017) (1)
- Drug Rediscovery Protocol: Expanded use of existing anticancer drugs (2019) (1)
- MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α (2014) (1)
- Abstract 3919: Liquid biopsy derived organoids as a potential platform for personalized cancer therapy in metastatic prostate cancer (2020) (1)
- Risk of metachronous contralateral breast cancer in patients with primary invasive lobular breast cancer: Results from a nationwide cohort (2022) (1)
- A nationwide prospective clinical trial on active surveillance in patients with non-intra-abdominal desmoid-type fibromatosis; the Grafiti trial (2022) (1)
- Trial Methodology in Soft Tissue Sarcomas; the ‘One Plus One is Three or Zero’ Phenomenon (2008) (1)
- 76. Circulating tumor cells in patients undergoing radical cystectomy for muscle-invasive bladder cancer: Interim results of the CirGuidance study (2016) (1)
- The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer (2022) (0)
- PMD31 - THE CONCORDANCE AND BUDGET IMPACT OF MULTIPLE ER, PR AND HER2 DETERMINATIONS IN DUTCH BREAST CANCER PATIENTS (2018) (0)
- Hemochromatosis gene (HFE) mutations and chemotherapy-related cardiovascular risk profile in testicular cancer survivors (TCS). (2016) (0)
- The role of circulating tumor cells in urothelial cell carcinoma of the bladder (2015) (0)
- Response to Goon et al. (2007) (0)
- HYPERTENSION AND RENAL FUNCTIONAL TOXICITY DURING VEGF-RECEPTOR INHIBITION WITH SUNITINIB: FOCUS ON ENDOTHELIN-1 AND OXIDATIVE STRESS: 5D.04 (2011) (0)
- Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting (2023) (0)
- Radiomics of Gastrointestinal Stromal Tumors; Risk Classification Based on Computed Tomography Images – A Pilot Study (2020) (0)
- Abstract P3-06-01: Hotspot mutations in PIK3CA are predictive for treatment outcome on aromatase inhibitors but not for tamoxifen (2012) (0)
- 2193 The prognostic value of mRNA expression of colorectal liver metastases for recurrence after surgical resection (2015) (0)
- 1328PAssociation of single nucleotide polymorphisms with efficacy in nivolumab-treated NSCLC patients (2017) (0)
- Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database (2022) (0)
- Whole Genome Sequencing in Personalized Oncology - Poster (2017) (0)
- Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors. (2023) (0)
- Androgen receptor expression in circulating tumor cells of metastatic breast cancer patients. (2018) (0)
- Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients (2018) (0)
- Prospective analysis in GIST patients on the role of alpha-1 acid glycoprotein (AGP) in imatinib exposure (2016) (0)
- The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies (2022) (0)
- Estimating The Drug Treatment Cost of Breast Cancer (2017) (0)
- clinical recommendations Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up (0)
- Abstract P4-02-02: Targeted molecular characterization of serum derived cell free DNA from metastatic breast cancer patients treated with first-line tamoxifen (2015) (0)
- Health-related Quality of Life of Patients with Non-intra-abdominal Desmoid-type Fibromatosis during Active Surveillance: Results of a Prospective Observational Study. (2023) (0)
- Abstract P1-02-02:ESR1mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression (2017) (0)
- University of Groningen Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines (2007) (0)
- 258 Macrocytosis as a potential parameter associated with outcome in the treatment with tyrosine kinase inhibitors (2015) (0)
- Mo1033 Tumor Antigen Expression Differs in Hepatocellular Carcinoma (HCC) Between Viral Hepatitis and Non-Viral Hepatitis Patients (2014) (0)
- Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors (2020) (0)
- 2575 Presence of androgen receptor splice variants in circulating tumor cells and response to cabazitaxel in castration-resistant prostate cancer (2015) (0)
- An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients (2016) (0)
- Radiomics of gastrointestinal stromal tumours, risk classification based on computed tomography images: A pilot study (2019) (0)
- Physicians’ Perspectives on Ethical Issues Regarding Expensive Anti-Cancer Treatments: A Qualitative Study (2022) (0)
- Contents Vol. 55, 2007 (2007) (0)
- Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels (2019) (0)
- Abstract OT1-1-02: PI3K-Akt-mTOR pathway analysis to obtain further insight in the efficacy of everolimus in combination with exemestane in metastatic, ER-positive breast cancer: A Dutch breast cancer research group (BOOG) study (2015) (0)
- Health-related quality of life issues of patients affected by desmoid-type fibromatosis: Experiences from two countries (2019) (0)
- Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients (2021) (0)
- Abstract 15185: Vascular Endothelial Growth Factor Inhibition Results in Systemic Hypertension Mediated by Alterations in Endothelin-1, but Not by Alterations in Nitric Oxide or Reactive Oxygen Species (2011) (0)
- This is a repository copy of Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients (2020) (0)
- Abstract A15: High miRNA-26a and low EZH2 expression levels are associated with favorable outcome to tamoxifen in advanced breast cancer (2010) (0)
- 472P Whole genome sequencing of metastatic CRC reveals footprints from the past and present with future clinical relevance (2020) (0)
- Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer (2021) (0)
- 304 INVITED Markers for Circulating Tumour Cells (2011) (0)
- Decreased expression of EZH2 is associated with ESR1 upregulation and response to anti-estrogens. (2009) (0)
- Phase I study of cisplatin (cDDP)/hyperthermia (HT)/lapatinib (Lap) in patients (pts) with recurrent carcinoma of the uterine cervix (rCC) in previously irradiated area (PIA). (2013) (0)
- Prognostic Value of Circulating Tumor Cell Characteristics May Be Biased by Their Quantity. (2021) (0)
- Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy An (2018) (0)
- 95P Optimizing selection of experimental treatment for patients with advanced cancer using whole genome sequencing (2021) (0)
- CLINICAL PRACTICE GUIDELINES Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up † (2018) (0)
- Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report (2017) (0)
- 198PThe prevalence of CD146 expression in breast cancer subtypes and its relation to outcome (2017) (0)
- OP125 Downregulation of EZH2 is associated with estrogen receptor upregulation and favourable outcome to tamoxifen in advanced breast cancer (2009) (0)
- Predictive and mechanistic factors of tyrosine kinase inhibitor (TKI)-induced macrocytosis. (2010) (0)
- 1492PThe differences in recurrence and survival of extremity liposarcoma subtypes (2017) (0)
- 10 Biosample collection in clinical trials (2010) (0)
- Corrigendum to: Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA (2021) (0)
- Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach (2019) (0)
- [Drug research in oncology; advances in the genome era]. (2014) (0)
- Sensitive detection of mitochondrial DNA variants for analysis of mitochondrial DNA-enriched extracts from frozen tumor tissue (2018) (0)
- MO26-2 Intra-tumoral clusters between CD20+ B cells and BCL6+ CD4+ T cells are prognostic in early oral cancers (2022) (0)
- Abstract P5-11-02: RecurrentESR1fusions in primary tumors; a promising predictive factor for outcome to first-line endocrine therapy? (2019) (0)
- GMP protocol to gene-engineer and process human T-cells revisited: medium critically determines yield, function and differentiation state of CD8+ T-cells (2014) (0)
- 169 INVITED Tips and Tricks How to be the Best – Clinical Oncologist (2011) (0)
- Health-Related Quality of Life Issues of Patients Affected by Desmoid-Type Fibromatosis; Experiences from Two Countries (2020) (0)
- P.2.h.001 Nitric oxide production and psychiatric symptomatology after interferon-a therapy in oncology patients (2007) (0)
- Abstract P2-01-17: Circulating tumor cell count and levels of circulating tumor DNA are complementary prognostic biomarkers in metastatic breast cancer - A pilot study (2022) (0)
- 124 Gastro-intestinal stromal tumors (GIST): the model for solid tumors treated with tyrosine kinase inhibitors (2009) (0)
- Abstract P4-02-16: High miRNA26A1 and Low EZH2 Expression Levels Are Associated with Favorable Outcome to Tamoxifen in Advanced Breast Cancer through Similar Molecular Pathways (2010) (0)
- Characteristics of circulating tumor DNA (ctDNA) in patients with ER-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (MBC) on different lines of endocrine treatment. (2019) (0)
- Abstract P4-09-07: Higher risk of metachronous contralateral breast cancer in patients with invasive lobular breast cancer (2019) (0)
- ‘Cost-effectiveness of the three EMA-approved adjuvant systemic therapies in patients with high-risk melanoma: a model-based economic evaluation’ (2022) (0)
- Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples (2020) (0)
- Gene expression profiles of circulating tumor cells in metastatic breast cancer patients. (2012) (0)
- Association of Surgeons from the Netherlands ( ASN ) : Najaarsvergadering , 26 November 2010 , Ede , the Netherlands Surgical treatment for colorectal carcinoma in the Netherlands ; which factors are most predictive for postoperative mortality ? (2011) (0)
- Long-term responders and survivors on pazopanib for soft tissue sarcomas (STS): Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. (2013) (0)
- ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients (2022) (0)
- Abstract 4433: Deregulated microRNAs in NF1 derived malignant peripheral nerve sheath tumors (MPNST) and their role in carcinogenesis (2017) (0)
- Abstract 453: Angiogenesis Inhibition-Induced Hypertension and Nephrotoxicity: Not All Antihypertensives are the Same (2013) (0)
- Mutation stratification of desmoid-type fibromatosis using a radiogenomics approach (2019) (0)
- Assessment of cfDNA in patients with metastatic colorectal cancer treated with cetuximab monotherapy. (2018) (0)
- Role of Tumor Localization on Outcome of Liposarcoma Patients, A Retrospective Cohort Study (2020) (0)
- Rates of survival throughout the years in soft tissue sarcoma with synchronous metastases: Results of a population-based study. (2017) (0)
- Abstract PD4-09: Non-invasive estrogen receptor assessment by [18F]-fluorestradiol(FES)-PET or circulating tumor cells predicts receptor status in patients with metastatic breast cancer (2019) (0)
- Subject Index Vol. 55, 2007 (2007) (0)
- Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial (2021) (0)
- Circulating tumour cells are associated with histopathological growth patterns of colorectal cancer liver metastases (2022) (0)
- Abstract CN3-2: Enumeration and characterization of CTCs (2010) (0)
- Abstract P4-15-12: Results from a randomized phase II study of the Dutch Breast Cancer Research Group (BOOG 2008-03): Concomitant trastuzumab, bevacizumab and paclitaxel (HAT) versus trastuzumab and bevacizumab, followed by trastuzumab, bevacizumab and paclitaxel (HA-HAT) a (2015) (0)
- B-cell clusters in the stroma at invasive tumour margin provide prognostic value in early-Stage oral-tongue cancer patients: The discovery and validation study (2019) (0)
- 1883 Prevalence and prognostic impact of HER2-positive circulating tumor cells in metastatic breast cancer patients with HER2-negative primary tumors (2015) (0)
- Association of hematological toxicity (tox) and outcome to doxorubicin (DOX) in advanced soft tissue sarcoma (STS): A retrospective analysis of the EORTC-Soft Tissue and Bone Sarcoma Group database. (2015) (0)
- Abstract P3-02-05: Evaluation of Gene Transcripts in Primary Tumors at Time of Diagnosis and Circulating Tumor Cells (CTCs) at Time of Metastatic Disease (2010) (0)
- The complete genomic landscape of metastatic prostate cancer pinpoints clinically targetable subgroups. (2018) (0)
- Integrated Genomic Profiling of Endocrine Therapy Response in Advanced Breast Cancer. (2009) (0)
- Circulating tumor and circulating endothelial cells as cellular biomarkers for outcome to neoadjuvant chemotherapy in locally advanced breast cancer. (2010) (0)
- Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing (2022) (0)
- 3439 Prognostic factors in soft tissue sarcoma patients with lung metastases only receiving first-line chemotherapy. An exploratory, retrospective analysis on fifteen trials of the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) (2015) (0)
- Abstract CT223: CCX872: Pharmacodynamic study of a potent and selective CCR2 antagonist in human volunteers and plans for phase Ib trial in patients with pancreatic cancer (2015) (0)
- Abstract CT113: The time to progression ratio: a new individualized volumetric parameter for early detection of clinical benefit of targeted therapies (2016) (0)
- EXTH-03. LOCAL ONCOLYTIC ADENOVIRUS TREATMENT AFFECTS BOTH THE INNATE AND ADAPTIVE ARMS OF THE IMMUNE SYSTEM AND PROVIDES AN AVENUE FOR ENHANCING IMMUNOTHERAPIES FOR GBM (2018) (0)
- Target KIT and ETV1 in gastrointestinal stromal tumors (GIST) (2012) (0)
- Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry (2016) (0)
- Clinical value of Zr-89-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma (2017) (0)
- A phase I study of the combination of daily oral sunitinib with intravenous ifosfamide in patients with advanced solid malignancies (2009) (0)
- Abstract 5673: In-depth analysis of the genomic landscape of 91 metastatic neuroendocrine tumors reveals subtype-heterogeneity and potential therapeutic targets (2020) (0)
- Abstract 3668: Relevance of BCAR4 in tamoxifen resistance and tumor aggressiveness of breast cancer (2010) (0)
- Abstract P2-03-14: Tumor-agnostic measurement of ctDNA levels in first line ER+, HER2- metastatic breast cancer patients as a marker for survival (2023) (0)
- OP-ANNO180096 51..67 (2018) (0)
- Use of serum proteins identified by proteomics to predict prognosis in patients with metastatic renal cell cancer (mRCC) and comparison to the currently used MSKCC survival model. (2009) (0)
- Abstract 528: Dose- And Salt-dependency Of Angiogenesis Inhibition-induced Blood Pressure Rise And Renal Toxicity (2014) (0)
- Abstract 2617: A multicenter project to test the validity and logistics surrounding the testing of AR-V7 mRNA expression in circulating tumor cells (2018) (0)
- Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA (2017) (0)
- University of Groningen RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer (2019) (0)
- In contrast to other soft tissue sarcomas, GIST shows enhanced numbers of immune checkpoint-negative CD8 T cells (2019) (0)
- OP-ANNO190315 661..671 (2019) (0)
- 5007 MicroRNA profiling of circulating tumor cells (CTC) present in large quantities of leukocytes (2009) (0)
- Additional file 2: Figure S2. of An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients (2016) (0)
- Clinical and laboratory studies on chemo-resistance and -sensitivity, and the role of TNF (1997) (0)
- 31P Genomic landscape and actionable targets as identified by whole genome sequencing and RNA sequencing in patients with advanced renal cell carcinoma (2021) (0)
- Gene expression profiles of primary tumors versus circulating tumor cells in metastatic breast cancer. (2014) (0)
- Abstract 5715: Circulating tumor DNA in colorectal cancer patients with resectable liver metastases: Preliminary results of the MIRACLE study (2023) (0)
- Down Regulation of EZH2 Is Associated with ESR1 Upregulation and Response to Endocrine Therapy in Breast Cancer. (2009) (0)
- Bridging the Translational Divide in Oncology: In Vivo Testing of Chemo-sensitivity (2020) (0)
- Higher risk of metachronous contralateral breast cancer in patients with invasive lobular breast cancer (2018) (0)
- Abstract A5: microRNA response to hypoxic stress in soft tissue sarcoma cells (2011) (0)
- Physical symptom burden in patients with desmoid-type fibromatosis and its impact on health-related quality of life and healthcare use. (2023) (0)
- Comprehensive pan-cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients (2019) (0)
- Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors (2019) (0)
- Abstract P1-09-20: An optimized workflow to analyzeESR1mutations in both circulating cell-free and circulating tumor cell DNA by digital PCR (2017) (0)
- 29P Plasma ESR1 mutations and outcome to first-line chemotherapy with bevacizumab and paclitaxel in patients with advanced ER-positive/HER2-negative breast cancer (2021) (0)
- Identifying t cell profiles that associate with clinical response to anti-PD-1 treatment in non-small cell lung carcinoma (NSCLC) patients. (2018) (0)
- The cost of expensive breast cancer drugs (2017) (0)
- mRNA expression profiles in circulating tumor cells (CTCs) of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AI). (2013) (0)
- Low expression levels of SIAH2 are associated with resistance to endocrine therapy in breast cancer (2008) (0)
- Improved circulating tumor cell detection by a combined EpCAM and MCAM CellSearch enrichment approach in breast cancer patients undergoing neoadjuvant chemotherapy detection using (2014) (0)
- In-depth analysis of the genomic landscape of 86 metastatic neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets (2020) (0)
- Abstract 4345: Molecular comparison of imatinib-naïve and resistant gastrointestinal stromal tumors: Differentially expressed microRNAs and mRNAs (2018) (0)
- Immune monitoring of experimental biological anti-tumor therapies (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stefan Sleijfer?
Stefan Sleijfer is affiliated with the following schools:
